This came up on my LinkedIn feed today. I don't think DXB can say they are the only one in phase 3 development. It's from a paper on the baseline features of PHASE 3 FIND CKD trial. This trial by bayer with finerenone has over 200 FSGS patients as well as other types of CKD. If it's positive, it'll be approved for all types of non diabetic CKD including FSGS. And it reads out before DMX FSGS trial....
I'm thinking of buying into this stock though. Not because I think the asset is that good, but the market seems captivated so some $$ to be made in near term if enough people believe in it. If anybody knows what's happening in China , trial IND 6-7 months ago but no announcements about patients recruited which I would have expected if they got the first Chinese patient.
Ann: Dimerix to present at Melbourne Twilight Investor Briefing, page-31
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.0¢ |
Change
-0.035(7.22%) |
Mkt cap ! $247.5M | |||
| Open | High | Low | Value | Volume |
| 48.5¢ | 48.5¢ | 44.5¢ | $1.897M | 4.104M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 79166 | 45.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.5¢ | 103477 | 2 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |